Skip to main content
Erschienen in: Diseases of the Colon & Rectum 1/2007

01.01.2007

Differences in Yeast Intolerance Between Patients with Crohn’s Disease and Ulcerative Colitis

verfasst von: Brigitt Brunner, M.D., Ulrich Scheurer, M.D., Frank Seibold, M.D.

Erschienen in: Diseases of the Colon & Rectum | Ausgabe 1/2007

Einloggen, um Zugang zu erhalten

Purpose

Alimentary factors, especially those modifying the intestinal flora, may influence the course of inflammatory bowel disease. It is known that T and B cells of patients with Crohn’s disease can be stimulated with the yeast antigen, mannan. We evaluated the impact of eating habits with special respect to food containing yeast on the course of inflammatory bowel disease.

Methods

Questionnaires were sent to 180 German-speaking patients of the Inflammatory Bowel Disease Outpatient Clinic at the University Hospital Bern, Switzerland. The following information was obtained by the questionnaires: (1) course of disease, (2) eating habits, (3) environmental data, and (4) inflammatory bowel disease questionnaire. The survey was anonymous.

Results

A total of 145 patients (80.5 percent 95 with Crohn’s disease, and 50 with ulcerative colitis) responded. Food items containing yeast were better tolerated by patients with ulcerative colitis than by patients with Crohn’s disease. A significant difference between the two groups was observed concerning food containing raw yeast (dough, P = 0.04; and pastry, P = 0.001).

Conclusions

Food items containing raw yeast led to more frequent problems for patients with Crohn’s disease than for patients with ulcerative colitis. This observation supports our previous data, which showed the stimulatory effect of the yeast antigen, mannan, on B and T cells of patients with Crohn’s disease but not of controls.
Literatur
1.
Zurück zum Zitat Calkins, BM 1989A meta-analysis of the role of smoking in inflammatory bowel diseaseDig Dis Sci3418411854PubMedCrossRef Calkins, BM 1989A meta-analysis of the role of smoking in inflammatory bowel diseaseDig Dis Sci3418411854PubMedCrossRef
2.
Zurück zum Zitat Sutherland, LR, Ramcharan, S, Bryant, H, Fick, G 1990Effect of cigarette smoking on recurrence of Crohn’s diseaseGastroenterology9811231128PubMed Sutherland, LR, Ramcharan, S, Bryant, H, Fick, G 1990Effect of cigarette smoking on recurrence of Crohn’s diseaseGastroenterology9811231128PubMed
3.
Zurück zum Zitat Sutton, CL, Yang, H, Li, Z, Rotter, JI, Targan, SR, Braun, J 2000Familial expression of anti-Saccharomyces cerevisiae mannan antibodies in affected and unaffected relatives of patients with Crohn’s diseaseGut465863PubMedCrossRef Sutton, CL, Yang, H, Li, Z, Rotter, JI, Targan, SR, Braun, J 2000Familial expression of anti-Saccharomyces cerevisiae mannan antibodies in affected and unaffected relatives of patients with Crohn’s diseaseGut465863PubMedCrossRef
4.
Zurück zum Zitat Vermeire, S, Joossens, S, Peeters, M, et al. 2001Comparative study of ASCA (anti-Saccharomyces cerevisiae antibody) assays in inflammatory bowel diseaseGastroenterology120827833PubMedCrossRef Vermeire, S, Joossens, S, Peeters, M,  et al. 2001Comparative study of ASCA (anti-Saccharomyces cerevisiae antibody) assays in inflammatory bowel diseaseGastroenterology120827833PubMedCrossRef
5.
Zurück zum Zitat Seibold, F, Stich, O, Hufnagl, R, Kamil, S, Scheurlen, M 2001Anti-Saccharomyces cerevisiae antibodies in inflammatory bowel disease: a family studyScand J Gastroenterol36196201PubMedCrossRef Seibold, F, Stich, O, Hufnagl, R, Kamil, S, Scheurlen, M 2001Anti-Saccharomyces cerevisiae antibodies in inflammatory bowel disease: a family studyScand J Gastroenterol36196201PubMedCrossRef
6.
Zurück zum Zitat Vermeire, S, Peeters, M, Vlictinck, R, et al. 2001Anti-Saccharomyces cerevisiae antibodies (ASCA), phenotypes of IBD, and intestinal permeability: a study in IBD familiesInflamm Bowel Dis7815PubMedCrossRef Vermeire, S, Peeters, M, Vlictinck, R,  et al. 2001Anti-Saccharomyces cerevisiae antibodies (ASCA), phenotypes of IBD, and intestinal permeability: a study in IBD familiesInflamm Bowel Dis7815PubMedCrossRef
7.
Zurück zum Zitat Peeters, M, Joossens, S, Vermeire, S, Vlietinck, R, Bossuyt, X, Rutgeerts, P 2001Diagnostic value of anti-Saccharomyces cerevisiae and antineutrophil cytoplasmic autoantibodies in inflammatory bowel diseaseAm J Gastroenterol96730734PubMedCrossRef Peeters, M, Joossens, S, Vermeire, S, Vlietinck, R, Bossuyt, X, Rutgeerts, P 2001Diagnostic value of anti-Saccharomyces cerevisiae and antineutrophil cytoplasmic autoantibodies in inflammatory bowel diseaseAm J Gastroenterol96730734PubMedCrossRef
8.
Zurück zum Zitat Annese, V, Andreoli, A, Andriulli, A, et al. 2001Familial expression of anti-Saccharomyces cerevisiae mannan antibodies in Crohn’s disease and ulcerative colitis: aGISC studyAm J Gastroenterol9624072412PubMedCrossRef Annese, V, Andreoli, A, Andriulli, A,  et al. 2001Familial expression of anti-Saccharomyces cerevisiae mannan antibodies in Crohn’s disease and ulcerative colitis: aGISC studyAm J Gastroenterol9624072412PubMedCrossRef
9.
Zurück zum Zitat Quinton, JF, Sendid, B, Reumaux, D, et al. 1998Anti-Saccharomyces cerevisiae mannan antibodies combined with antineutrophil cytoplasmic autoantibodies in inflammatory bowel disease: prevalence and diagnostic roleGut42788791PubMedCrossRef Quinton, JF, Sendid, B, Reumaux, D,  et al. 1998Anti-Saccharomyces cerevisiae mannan antibodies combined with antineutrophil cytoplasmic autoantibodies in inflammatory bowel disease: prevalence and diagnostic roleGut42788791PubMedCrossRef
10.
Zurück zum Zitat Konrad, A, Rutten, C, Flogerzi, B, Styner, M, Goke, B, Seibold, F 2004Immune sensitization to yeast antigens in ASCA-positive patients with Crohn’s diseaseInflamm Bowel Dis1097105PubMedCrossRef Konrad, A, Rutten, C, Flogerzi, B, Styner, M, Goke, B, Seibold, F 2004Immune sensitization to yeast antigens in ASCA-positive patients with Crohn’s diseaseInflamm Bowel Dis1097105PubMedCrossRef
11.
Zurück zum Zitat Seibold, F, Konrad, A, Flogerzi, B, et al. 2004Genetic variants of the mannan-binding lectin are associated with immune reactivity to mannans in Crohn’s diseaseGastroenterology12710761084PubMedCrossRef Seibold, F, Konrad, A, Flogerzi, B,  et al. 2004Genetic variants of the mannan-binding lectin are associated with immune reactivity to mannans in Crohn’s diseaseGastroenterology12710761084PubMedCrossRef
12.
13.
Zurück zum Zitat Tada, H, Nemoto, E, Shimauchi, H, et al. 2002Saccharomyces cerevisiae and Candida albicans derived mannan induced production of tumor necrosis factor alpha by human monocytes in a CD 14- and Toll-like receptor 4- dependent mannerMicrobiol Immunol46503512PubMed Tada, H, Nemoto, E, Shimauchi, H,  et al. 2002Saccharomyces cerevisiae and Candida albicans derived mannan induced production of tumor necrosis factor alpha by human monocytes in a CD 14- and Toll-like receptor 4- dependent mannerMicrobiol Immunol46503512PubMed
14.
Zurück zum Zitat Franchimont, D, Vermeire, S, Housni, H, et al. 2004Deficient host-bacteria interactions in inflammatory bowel disease? The toll-like receptor (TLR)-4 Asp299gly polymorphism is associated with Crohn’s disease and ulcerative colitisGut53987992PubMedCrossRef Franchimont, D, Vermeire, S, Housni, H,  et al. 2004Deficient host-bacteria interactions in inflammatory bowel disease? The toll-like receptor (TLR)-4 Asp299gly polymorphism is associated with Crohn’s disease and ulcerative colitisGut53987992PubMedCrossRef
15.
Zurück zum Zitat Mitchell, A, Guyatt, G, Singer, J, et al. 1988Quality of life in patients with inflammatory bowel diseaseJ Clin Gastroenterol10306310PubMedCrossRef Mitchell, A, Guyatt, G, Singer, J,  et al. 1988Quality of life in patients with inflammatory bowel diseaseJ Clin Gastroenterol10306310PubMedCrossRef
16.
Zurück zum Zitat Guyatt, G, Mitchell, A, Irvine, EJ, et al. 1989A new measure of health status for clinical trials in inflammatory bowel diseaseGastroenterology96804810PubMed Guyatt, G, Mitchell, A, Irvine, EJ,  et al. 1989A new measure of health status for clinical trials in inflammatory bowel diseaseGastroenterology96804810PubMed
17.
Zurück zum Zitat Kocourek, J, Ballou, CE 1969Method for fingerprinting yeast cell wall mannansJ Bacteriol10011751181PubMed Kocourek, J, Ballou, CE 1969Method for fingerprinting yeast cell wall mannansJ Bacteriol10011751181PubMed
18.
Zurück zum Zitat Mayberry, JF, Rhodes, J 1984Epidemiological aspects of Crohn’s disease: a review of literatureGut25886899PubMed Mayberry, JF, Rhodes, J 1984Epidemiological aspects of Crohn’s disease: a review of literatureGut25886899PubMed
19.
Zurück zum Zitat Calkins, BM, Medeloff, AI 1986Epidemiology of inflammatory bowel diseaseEpidemiol Rev86091PubMed Calkins, BM, Medeloff, AI 1986Epidemiology of inflammatory bowel diseaseEpidemiol Rev86091PubMed
20.
Zurück zum Zitat Barclay, GR, McKenzie, H, Pennington, J, Parratt, D, Pennington, CR 1992The effect of dietary yeast on the activity of stable chronic Crohn’s diseaseScand J Gastroenterol27196200PubMed Barclay, GR, McKenzie, H, Pennington, J, Parratt, D, Pennington, CR 1992The effect of dietary yeast on the activity of stable chronic Crohn’s diseaseScand J Gastroenterol27196200PubMed
21.
Zurück zum Zitat Vasiliauskas, EA, Kam, LY, Karp, LC, Gaiennie, J, Yang, H, Targan, SR 2000Marker antibody expression stratifies Crohn’s disease into immunologically homogenous subgroups with distinct clinical characteristicsGut47487496PubMedCrossRef Vasiliauskas, EA, Kam, LY, Karp, LC, Gaiennie, J, Yang, H, Targan, SR 2000Marker antibody expression stratifies Crohn’s disease into immunologically homogenous subgroups with distinct clinical characteristicsGut47487496PubMedCrossRef
22.
Zurück zum Zitat Walker, LJ, Aldhous, MC, Drummond, HE, et al. 2004Anti-Saccharomyces cerevisiae antibodies (ASCA) in Crohn’s disease are associated with disease severity but not NOD2/CARD15 mutationsClin Exp Immunol135490496PubMedCrossRef Walker, LJ, Aldhous, MC, Drummond, HE,  et al. 2004Anti-Saccharomyces cerevisiae antibodies (ASCA) in Crohn’s disease are associated with disease severity but not NOD2/CARD15 mutationsClin Exp Immunol135490496PubMedCrossRef
23.
Zurück zum Zitat Zholudev, A, Zurakowski, D, Young, W, Leichtner, A, Bousvaros, A 2004Serologic testing with ANCA, ASCA, and anti-OmpC in children and young adults with Crohn’s disease and ulcerative colitis: diagnostic value and correlation with disease phenotypeAm J Gastroenterol9922352241PubMedCrossRef Zholudev, A, Zurakowski, D, Young, W, Leichtner, A, Bousvaros, A 2004Serologic testing with ANCA, ASCA, and anti-OmpC in children and young adults with Crohn’s disease and ulcerative colitis: diagnostic value and correlation with disease phenotypeAm J Gastroenterol9922352241PubMedCrossRef
Metadaten
Titel
Differences in Yeast Intolerance Between Patients with Crohn’s Disease and Ulcerative Colitis
verfasst von
Brigitt Brunner, M.D.
Ulrich Scheurer, M.D.
Frank Seibold, M.D.
Publikationsdatum
01.01.2007
Erschienen in
Diseases of the Colon & Rectum / Ausgabe 1/2007
Print ISSN: 0012-3706
Elektronische ISSN: 1530-0358
DOI
https://doi.org/10.1007/s10350-006-0749-1

Weitere Artikel der Ausgabe 1/2007

Diseases of the Colon & Rectum 1/2007 Zur Ausgabe

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare
CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare
CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare
CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.